Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02616172Phase 1Suspended

Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss

Role: lead

NCT02460484Phase 1Suspended

Safety of Autologous Human Umbilical Cord Blood Treatment for Perinatal Arterial Ischemic Stroke

Role: lead

NCT02038972Phase 1Completed

Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss

Role: lead

All 3 trials loaded